Statistics from Altmetric.com
Cardiovascular safety of sitagliptin demonstrated
A number of novel hypoglycaemic agents have entered into usage over the last decade and are now in widespread use in clinical practice. Amongst these are the dipeptidyl peptidase 4 (DPP-4) inhibitors, which improve glycaemic control by increasing endogenous insulin secretion and suppressing glucagon levels. Data from recent studies has questioned the cardiovascular safety of DPP-4 inhibitors with meta-analyses suggesting increased rates of heart failure hospitalization with use of DPP-4 inhibitors. In large Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS), the cardiovascular safety of the DPP-4 inhibitor sitagliptin was assessed when added to usual therapy in patients with type II diabetes and a history of cardiovascular disease. In this international, double-blind trial, 14,671 patients were randomized to either sitagliptin or …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.